ProMIS Neurosciences is trading at $8.95, up +10.63% on October 21, 2026, as the move coincides with biotech-sector strength. - The XBI ETF is up 2.10%, supported by M&A activity and positive clinical-trial news. - No new company-specific announcement explaining the rise was found. The October 6 chief commercial officer appointment is prior news, not a confirmed catalyst for this session. - Broader markets are also higher, adding positive sentiment.